We are committed to “un-rare” rare diseases by using our worldwide knowledge in the rare disease market, understanding the epidemiology, analyzing clinical heterogeneity of the more than 3800 diseases and developing innovative biomarkers.
The combination of genomics, proteomics and metabolomics provides deep insights in the pathogenesis of rare hereditary diseases. The value in such a holistic diagnostics process has resulted in the shift from pure data generation to deep knowledge, IT-based interpretation workflows in diagnostics.
Furthermore, the development of biomarkers is the central element to bring rationality to treatment decisions in rare disease patients. Only a detailed, science-based understanding of the genetic basis and the clinical phenotype of rare hereditary diseases will provide critical knowledge that will guide every stage of drug development.
At the core of our knowledge based system is our global data repository (CentoMD® and CentoPharma®), which includes epidemiologic, phenotypic, and genetic data and allows us to assemble a knowledge base in rare hereditary diseases.
We collect this detailed level of data in our repository through our easy-to-use CentoCard®, a proprietary CE-marked dried blood spot collection system.
Our vision is to use our precision medicine techniques to build the most accurate diagnostic system to benefit our patients and to accelerate the development of new treatment solutions.